Please select the option that best describes you:
Since the publication of DESTINY-Breast-04 have you implemented new institutional practices for characterization of HER2-low disease given known limitations in pathologist IHC evaluation?
Answer from: Medical Oncologist at Community Practice
Since the publication of DESTINY-Breast04, new institutional practices for the characterization of HER2-low disease have been implemented in my practice. The Ventana antibody is utilized, with the approved companion diagnostic recommended. However, it should be noted that the study found the Ve...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
To my knowledge, the process for IHC staining and evaluation by pathology have not changed at my institution. As a medical oncologist, the biggest change to my practice has been the need to review prior pathology results on my HER2 negative patients to determine if IHC was assessed previously or if ...
Answer from: Medical Oncologist at Community Practice
We used to perform FISH alone to determine the HER2 status of metastatic breast cancer; now we perform both FISH and IHC.